Instil Bio, Inc. (TIL)
NASDAQ: TIL · IEX Real-Time Price · USD
10.40
-0.20 (-1.89%)
At close: Apr 25, 2024, 3:21 PM
10.39
-0.01 (-0.10%)
After-hours: Apr 25, 2024, 4:00 PM EDT
Company Description
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies.
The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer.
It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Instil Bio, Inc.
| Country | United States |
| Founded | 2018 |
| IPO Date | Mar 19, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 49 |
| CEO | Bronson Crouch |
Contact Details
Address: 3963 Maple Avenue, Suite 350 Dallas, Texas 75219 United States | |
| Phone | (972) 499-3350 |
| Website | instilbio.com |
Stock Details
| Ticker Symbol | TIL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $20.00 |
| CIK Code | 0001789769 |
| CUSIP Number | 45783C101 |
| ISIN Number | US45783C2008 |
| Employer ID | 83-2072195 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Bronson Crouch | Chairman and Chief Executive Officer |
| Dr. Sandeep Laumas M.D. | Chief Financial Officer and Chief Business Officer |
| Dr. Mark E. Dudley Ph.D. | Chief Scientific Officer |
| Dr. Robert Hawkins MBBS, Ph.D. | Head of Research and Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 2, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Mar 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 21, 2024 | 10-K | Annual Report |
| Mar 21, 2024 | 8-K | Current Report |
| Feb 14, 2024 | 8-K | Current Report |
| Jan 18, 2024 | 8-K | Current Report |
| Jan 16, 2024 | 8-K | Current Report |
| Dec 8, 2023 | 8-K | Current Report |
| Nov 27, 2023 | 8-K | Current Report |
| Nov 13, 2023 | 10-Q/A | [Amend] Quarterly report |